Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glucosaminyl-muramyl dipeptide acid
- Development stage
- Unknown
- Lead developer
- Peptek
- Modality
- Small Molecules, Peptides
- Administration
- Subcutaneous, Topical
01
Overview
Glucosaminyl-muramyl dipeptide acid (GMDP-A), chemically known as N-acetylglucosaminyl-N-acetylmuramyl-L-alanyl-D-glutamic acid, is a synthetic glycopeptide and a derivative of glucosaminylmuramyl dipeptide (GMDP). Developed by Peptek, GMDP-A acts as an agonist of the intracellular Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) receptor, a key sensor of innate immunity. It modulates immune responses by activating natural killer (NK) cells and other immune cells. GMDP-A has been investigated as an immunomodulator and biological response modifier in cancer therapy to enhance the efficacy of cytostatic chemotherapy, and it is also utilized as a postbiotic ingredient in anti-aging cosmetic formulations to restore the epidermal barrier and improve skin hydration and elasticity.
- Other names
- N-acetylglucosaminyl-N-acetylmuramyl-L-alanyl-D-glutamic acidglucosaminylmuramyl dipeptide acidglyukozaminilmuramildipeptid kislotaглюкозаминилмурамилдипептид-кислота
02
Targets
NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)
Beyond the preview
Go deeper on glucosaminyl-muramyl dipeptide acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glucosaminyl-muramyl dipeptide acid.